Mosaic ImmunoEngineering Inc.
For the period ended Dec 31, 2025. Filed Apr 15, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Apr 15, 2026
CPMVStored price and day change unavailable
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| Dated: April 15, 2026 | MOSAIC IMMUNOENGINEERING, INC. /s/ Steven King Steven King. President, Chief Executive Officer and Chief Financial Officer, Director (Principal Executive Officer and Principal Financial and Accounting Officer) |
|---|
Index to Consolidated Financial Statements
For the Years Ended December 31, 2025 and 2024
| Page | |
| Report of Independent Registered Public Accounting Firm (Rose, Snyder & Jacobs LLP PCAOB ID#: 468) | F-2 |
|---|---|
| Financial Statements: | |
| Consolidated Balance Sheets | F-3 |
| Consolidated Statements of Operations | F-4 |
| Consolidated Statements of Stockholders’ Deficit | F-5 |
| Consolidated Statements of Cash Flows | F-6 |
| Notes to Consolidated Financial Statements | F-7 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.